To review the efficacy and safety of inhaled furosemide in the treatment of acute respiratory distress and possible bronchopulmonary dysplasia (BPD) in preterm neonates receiving ventilator and oxygen support.
DATA SOURCES:
A MEDLINE search was performed from January 1966 to December 1998 using the key words inhaled or aerosolized furosemide, BPD, preterm, neonate, and infant newborn.
STUDY SELECTION AND DATA EXTRACTION:
All clinical trials involving the use of inhaled furosemide in ventilator- and oxygen-dependent preterm neonates with acute respiratory distress and possible BPD were evaluated.
DATA SYNTHESIS:
Inhaled furosemide 1 and 2 mg/kg has improved pulmonary function in preterm neonates without significant adverse effects. However, only a single dose of inhaled furosemide was used in these trials, and pulmonary functions were monitored for only two or four hours after administration.
CONCLUSIONS:
Inhaled furosemide may be effective, but studies are needed to determine the optimal dosage regimen and long-term risks and benefits of its use in these patients.
AbmanSHGroothiusJR. Pathophysiology and treatment of bronchopulmonary dysplasia: Current issues. Pediatr Clin North Am1994;41: 277–315.
2.
DeLemosRACoalsonJJ. Contributions of experimental models to our understanding of the pathogenesis and treatment of BPD. Clin Perinatol1992;19:521–39.
3.
PhilipAGS. Oxygen plus pressure plus time: The etiology of BPD. Pediatrics1975;55:44–50.
4.
NorthwayWHJrRosanRCPorterDY. Pulmonary disease following respiratory therapy of hyaline membrane disease: Bronchopulmonary dysplasia. N Engl J Med1967;267:357–68.
5.
BarringtonKJFinerNN. Treatment of bronchopulmonary dysplasia. A review. Clin Perinatol1998;25:177–203.
6.
ShenanATDunnMSOhlssonALennoxKHoskinsEM. Abnormal pulmonary outcomes in premature infants: Prediction from oxygen requirement in the neonatal period. Pediatrics1988;82:527–32.
7.
AlsHLawhornGBrownEGibesRDuffyFHMcAnultyGIndividualized behavioral and environmental care for the very low birth weight preterm infant at high risk for bronchopulmonary dysplasia: Neonatal intensive care unit and developmental outcome. Pediatrics1986;78:1123–32.
8.
KoopsBLAbramSHAccursoFJ. Outpatient management and follow up of bronchopulmonary dysplasia. Clin Perinatol1984;11:101–22.
9.
MotoyamaEKFortMDKleshKWMutichRLGuthrieRD. Early onset of airway reactivity in premature infants with bronchopulmonary dysplasia. Am Rev Respir Dis1987;136:50–7.
10.
BryanMHHardieJJReillyBJSwyerPR. Pulmonary function studies during the first year of life in infants recovering from the respiratory distress syndrome. Pediatrics1973;52:169–78.
11.
MorrayJPFoxNWKettrickRGDowageJJ. Improvement in lung mechanics as a function of age in the infant with severe bronchopulmonary dysplasia. Pediatr Res1982;16:290–4.
12.
WattJLAriagnoRLBradyJL. Chronic pulmonary disease in neonates after artificial ventilation: Distribution of ventilation and pulmonary interstitial emphysema. Pediatrics1977;60:273–81.
13.
HarrodJRL'HeureuxPWangensteenODHuntCE. Long-term follow up of severe respiratory distress with IPPB. J Pediatr1974;84:277–86.
14.
MelnickGPickoffASFerrerPLPeyserJBancalariEGelbandH. Normal pulmonary vascular resistance and left ventricular hypertrophy in young infants with bronchopulmonary dysplasia: An echocardiographic and pathologic study. Pediatrics1980;66:589–96.
15.
AbmanSHWaradyBALumGMKoopsBL. Systemic hypertension in infants with bronchopulmonary dysplasia. J Pediatr1984;70:708–12.
16.
GrossSJIannuzziDMKveslisDAAnbarRD. Effect of preterm birth on pulmonary function at school age: A prospective controlled study. J Pediatr1998;133:188–92.
17.
DavisJMSinkinRAArandaJV. Drug therapy for BPD. Pediatr Pulmonol1990;8:117–25.
18.
RushMGHazinskiTA. Current therapy of BPD. Clin Perinatol1992;19:563–90.
McCannEMLewisKDemingDDDonovanMJBradyJP. Controlled trial of furosemide therapy in infants with chronic lung disease. J Pediatr1985;107:957–61.
21.
NajakZDHarrisEMLazzaraAJrPrittAW. Pulmonary effect of furosemide in preterm infants with lung disease. J Pediatr1983;102:758–63.
22.
AlbersheimSGSolimanoAJSharmaAKSmythJARotschildAWoodBJRandomized, double blind controlled trial of long term diuretic therapy for BPD. J Pediatr1989;115:615–20.
23.
EngelhardtBElliotSHazinskiTA. Short and long term effects of furosemide on lung function in infants with BPD. J Pediatr1986;109: 1034–9.
24.
KaoLCWarburtonDWChengMHCedenoCPlatzkerAKeensTG. Effects of oral diuretics on pulmonary mechanics in infants with chronic BPD: Results of a double blind, crossover sequential trial. Pediatrics1984;74:37–44.
25.
BlandRDMcMillanDDBressackMA. Decreased pulmonary transvascular fluid filtration in awake newborn lambs after intravenous furosemide. J Clin Invest1978;62:601–9.
26.
SladenALaverMBPontoppidanH. Pulmonary complications and water retention in prolonged mechanism ventilation. N Engl J Med1968;279:448–53.
27.
HufnagleKGKhanSNPennDCacciarelliAWilliamsP. Renal calcifications: A complication of long term furosemide therapy in premature infants. Pediatrics1982;70:360–3.
28.
BackstromMCKuuselaALMakiR. Metabolic bone disease of prematurity. Ann Med1996;28:275–82.
29.
CoeFLCanterburyJMFirpoJJReissE. Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria. J Clin Invest1973;53: 131–42.
30.
VenkataramanPSHanBKTsangRCDaughertyCC. Secondary hyperthyroidism and bone disease in infants receiving long-term furosemide therapy. Am J Dis Child1983;137:1157–61.
31.
BiancoSVaghiARobuschiMPasargiklianM. Prevention of exercise induced bronchoconstriction by inhaled furosemide. Lancet1988;2:252–5.
32.
GrubbeREHopeRDaveNKBrennanBBewtraATownleyR. Effect of inhaled furosemide on bronchial response to methacholine and cold air hyperventilation challenges. J Allergy Clin Immunol1990;85: 881–4.
33.
BiancoSPieroniMGRefiniRMRottolliLSestiniP. Protective effect of inhaled furosemide on allergen induced early and late asthmatic reactions. N Engl J Med1989;321:1069–73.
34.
RastogiALuayonMAjayiOAPildesRS. Nebulized furosemide in infants with bronchopulmonary dysplasia. J Pediatr1994;125:976–9.
35.
PrabhuVGKeszlerMDhanireddyR. Pulmonary function changes after nebulised and intravenous furosemide in ventilated premature infants. Arch Dis Child1997;77:(F)32–5.
36.
KugelmanADurandMGargM. Pulmonary effect of inhaled furosemide in ventilated infants with severe bronchopulmonary dysplasia. Pediatrics1997;99:71–5.
37.
OkhiYNakoYKoizumiTMorikawaA. The effect of aerosolized furosemide in infants with chronic lung disease. Acta Paediatr1997;86: 656–60.
38.
PrabhuVGKeszlerMDhanireddyR. Dose-dependent evaluation of the effects of nebulized furosemide on pulmonary function in ventilated preterm infants. J Perinatol1998;18:357–60.
39.
PatelHYehTFJainRPildesR. Pulmonary and renal responses to furosemide in infants with stage III—IV BPD. Am J Dis Child1985;139: 917–9.
40.
RushMGEngelhardtBParkerRA. Double blind placebo-controlled trial of alternate day furosemide in infants with chronic bronchopulmonary dysplasia. J Pediatr1990;117:112–8.
41.
PolosaRLauLCKHolgateST. Inhibition of adenosine 5'-monophosphate and methacholine induced bronchoconstriction in asthma by inhaled furosemide. Eur Respir J1990;3:665–72.
42.
PavordIDWisniewskiATattersfieldAE. Inhaled furosemide and exercise induced asthma: Evidence of a role for inhibitory prostanoids. Thorax1992;47:797–800.
43.
AndersonSDTempleDMWeiHE. Inhibition of furosemide of inflammatory mediators from lung fragments (letter). N Engl J Med1991;324:131.
44.
MosacatoGDellabiancaAFalagianiPMistrelloGRampullaC. Inhaled furosemide prevents both the bronchoconstriction and the increase in neutrophil chemotactic activity induced by ultrasonic ‘fog’ of distilled water in asthmatics. Am Rev Respir Dis1991;143:561–6.
